Dariohealth Corp (DRIO)

$0.86

Market is closed - opens 8 PM, 14 Nov 2024

Performance

  • $0.84
    $0.95
    $0.86
    downward going graph

    2.33%

    Downside

    Day's Volatility :11.57%

    Upside

    9.46%

    downward going graph
  • $0.71
    $2.60
    $0.86
    downward going graph

    18.02%

    Downside

    52 Weeks Volatility :72.88%

    Upside

    66.92%

    downward going graph

Returns

PeriodDariohealth CorpSector (Health Care)Index (Russel 2000)
3 Months
-5.36%
-2.6%
0.0%
6 Months
-50.57%
2.6%
0.0%
1 Year
-16.83%
15.9%
0.0%
3 Years
-94.82%
10.0%
-26.7%

Highlights

Market Capitalization
27.9M
Book Value
$1.87
Earnings Per Share (EPS)
-1.14
PEG Ratio
0.0
Wall Street Target Price
3.83
Profit Margin
-205.62%
Operating Margin TTM
-162.06%
Return On Assets TTM
-34.74%
Return On Equity TTM
-74.91%
Revenue TTM
23.1M
Revenue Per Share TTM
0.63
Quarterly Revenue Growth YOY
111.00000000000001%
Gross Profit TTM
14.0M
EBITDA
-53.6M
Diluted Eps TTM
-1.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.03
EPS Estimate Next Year
-0.8
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Dariohealth Corp(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 345.35%

Current $0.86
Target $3.83

Company Financials

FY18Y/Y Change
Revenue
7.4M
↑ 43.02%
Net Income
-17.8M
↑ 13.09%
Net Profit Margin
-240.78%
↑ 63.73%
FY19Y/Y Change
Revenue
7.6M
↑ 2.23%
Net Income
-17.8M
↓ 0.2%
Net Profit Margin
-235.04%
↑ 5.74%
FY20Y/Y Change
Revenue
7.6M
↑ 0.22%
Net Income
-29.0M
↑ 63.15%
Net Profit Margin
-382.62%
↓ 147.58%
FY21Y/Y Change
Revenue
20.5M
↑ 170.76%
Net Income
-76.8M
↑ 164.81%
Net Profit Margin
-374.21%
↑ 8.41%
FY22Y/Y Change
Revenue
27.7M
↑ 34.82%
Net Income
-62.2M
↓ 18.98%
Net Profit Margin
-224.88%
↑ 149.33%
FY23Y/Y Change
Revenue
20.4M
↓ 26.41%
Net Income
-54.9M
↓ 11.79%
Net Profit Margin
-269.56%
↓ 44.68%
Q2 FY23Q/Q Change
Revenue
6.2M
↓ 12.94%
Net Income
-16.6M
↓ 233.66%
Net Profit Margin
-269.59%
↓ 445.19%
Q3 FY23Q/Q Change
Revenue
3.5M
↓ 42.82%
Net Income
16.9M
↓ 201.92%
Net Profit Margin
480.5%
↑ 750.09%
Q4 FY23Q/Q Change
Revenue
3.6M
↑ 2.79%
Net Income
-12.0M
↓ 170.99%
Net Profit Margin
-331.88%
↓ 812.38%
Q1 FY24Q/Q Change
Revenue
5.8M
↑ 59.24%
Net Income
-6.9M
↓ 42.36%
Net Profit Margin
-120.13%
↑ 211.75%
Q2 FY24Q/Q Change
Revenue
6.3M
↑ 8.63%
Net Income
-3.4M
↓ 51.3%
Net Profit Margin
-53.86%
↑ 66.27%
Q3 FY24Q/Q Change
Revenue
7.4M
↑ 18.67%
Net Income
14.6M
↓ 533.61%
Net Profit Margin
196.79%
↑ 250.65%
FY18Y/Y Change
Total Assets
14.1M
↑ 102.52%
Total Liabilities
5.2M
↑ 71.22%
FY19Y/Y Change
Total Assets
24.6M
↑ 74.38%
Total Liabilities
5.7M
↑ 9.9%
FY20Y/Y Change
Total Assets
35.4M
↑ 44.11%
Total Liabilities
7.3M
↑ 27.86%
FY21Y/Y Change
Total Assets
100.8M
↑ 184.61%
Total Liabilities
15.2M
↑ 109.79%
FY22Y/Y Change
Total Assets
119.2M
↑ 18.28%
Total Liabilities
39.2M
↑ 157.47%
FY23Y/Y Change
Total Assets
96.4M
↓ 19.13%
Total Liabilities
38.2M
↓ 2.42%
Q2 FY23Q/Q Change
Total Assets
117.2M
↑ 8.47%
Total Liabilities
38.8M
↑ 7.72%
Q3 FY23Q/Q Change
Total Assets
106.5M
↓ 9.09%
Total Liabilities
38.5M
↓ 0.74%
Q4 FY23Q/Q Change
Total Assets
96.4M
↓ 9.5%
Total Liabilities
38.2M
↓ 0.58%
Q1 FY24Q/Q Change
Total Assets
137.0M
↑ 42.1%
Total Liabilities
58.9M
↑ 54.09%
Q2 FY24Q/Q Change
Total Assets
122.1M
↓ 10.83%
Total Liabilities
54.1M
↓ 8.23%
FY18Y/Y Change
Operating Cash Flow
-11.5M
↑ 8.01%
Investing Cash Flow
6.0K
↓ 102.74%
Financing Cash Flow
18.7M
↑ 39.22%
FY19Y/Y Change
Operating Cash Flow
-15.7M
↑ 37.1%
Investing Cash Flow
-113.0K
↓ 1983.33%
Financing Cash Flow
25.2M
↑ 34.7%
FY20Y/Y Change
Operating Cash Flow
-17.7M
↑ 12.79%
Investing Cash Flow
-1.6M
↑ 1335.4%
Financing Cash Flow
27.5M
↑ 9.11%
FY21Y/Y Change
Operating Cash Flow
-50.4M
↑ 184.22%
Investing Cash Flow
-8.1M
↑ 401.48%
Financing Cash Flow
65.8M
↑ 138.73%
FY22Y/Y Change
Operating Cash Flow
-47.8M
↓ 5.09%
Investing Cash Flow
-573.0K
↓ 92.96%
Financing Cash Flow
61.9M
↓ 5.82%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.6M
↑ 102.56%
Investing Cash Flow
4.2M
↓ 195.8%
Financing Cash Flow
19.4M
↓ 1499.42%

Technicals Summary

Sell

Neutral

Buy

Dariohealth Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dariohealth Corp
Dariohealth Corp
-16.83%
-50.57%
-16.83%
-94.82%
-79.41%
Solventum Corp
Solventum Corp
1.89%
11.97%
2.32%
2.32%
2.32%
Doximity, Inc.
Doximity, Inc.
38.35%
152.5%
143.09%
-17.97%
9.53%
Veeva Systems Inc.
Veeva Systems Inc.
12.4%
16.02%
42.27%
-25.04%
59.48%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-7.31%
4.8%
21.3%
40.39%
40.39%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dariohealth Corp
Dariohealth Corp
NA
NA
0.0
-1.03
-0.75
-0.35
NA
1.87
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Doximity, Inc.
Doximity, Inc.
70.4
70.4
2.42
0.9
0.19
0.12
NA
5.15
Veeva Systems Inc.
Veeva Systems Inc.
63.33
63.33
1.36
4.76
0.13
0.06
NA
32.04
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
23.39
23.39
2.15
4.3
0.22
0.06
0.0
18.2
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dariohealth Corp
Dariohealth Corp
Buy
$27.9M
-79.41%
NA
-205.62%
Solventum Corp
Solventum Corp
Hold
$10.8B
2.32%
NA
15.73%
Doximity, Inc.
Doximity, Inc.
Hold
$11.4B
9.53%
70.4
33.69%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$38.4B
59.48%
63.33
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.0B
40.39%
23.39
8.56%

Insights on Dariohealth Corp

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 3.51M → 7.42M (in $), with an average increase of 15.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -12.00M → 14.60M (in $), with an average increase of 100.6% per quarter

  • Vs DOCS

    In the last 1 year, Doximity, Inc. has given 143.1% return, outperforming this stock by 159.9%

  • Vs DOCS

    In the last 3 years, Dariohealth Corp has experienced a drawdown of -94.9%, however Doximity, Inc. resisted the overall trend and outperformed by 73.9%

Institutional Holdings

  • Nantahala Capital Management, LLC

    15.27%
  • Appian WAY Asset Management

    4.39%
  • Phoenix Financial Ltd

    3.60%
  • Y.D. More Investments Ltd

    3.13%
  • Clal Insurance Enterprises Holdings Ltd

    1.64%
  • Vanguard Group Inc

    1.16%

Company Information

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.

Organization
Dariohealth Corp
Employees
276
CEO
Mr. Erez Raphael
Industry
Health Technology

FAQs